# BH-30236

Source: https://onco.cc/drugs/bh-30236/  
OnCo record `bh-30236` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BH-30236 is an experimental small molecule from BlossomHill Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes.

## Summary

BH-30236 is a small molecule (oral, macrocyclic) from BlossomHill Therapeutics. An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b first-in-human trial, recruiting (registry checked 3 Nov 2026); tested alone and with venetoclax. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BH-30236
- Modality: Small molecule (oral, macrocyclic)
- Mechanism: An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy.

## Sources

- BlossomHill Therapeutics: bhtherapeutics.com: https://www.bhtherapeutics.com/pipeline
- BlossomHill Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06501196
- ClinicalTrials.gov: trials of BH-30236: https://clinicaltrials.gov/search?intr=BH-30236

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- companies: [BlossomHill Therapeutics](https://onco.cc/companies/blossomhill-therapeutics/)
- trials: [A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome](https://onco.cc/trials/nct06501196/)

---
JSON: https://onco.cc/api/v1/entities/bh-30236.json